

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 10

PATENT NO. : 7,012,133
APPLICATION NO.: 08/963,656
ISSUE DATE : March 14, 2006
INVENTOR(S) : Craig J. Gerard et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<110> GERARD, CRAIG J.
GERARD, NORMA P.
MACKAY, CHARLES R.
PONATH, PAUL D.
POST, THEODORE W.
QIN, SHIXIN

<120> ANTIBODIES TO C-C CHEMOKINE RECEPTOR 3 PROTEIN

<130> 079259-0040

<140> 08/963,656

<141> 1997-11-03

<150> 08/720,565

<151> 1996-09-30

<150> PCT/US96/00608

<151> 1996-01-19

<150> 08/375,199

<151> 1995-01-19

<160> 18

<170> PatentIn version 3.5

MAILING ADDRESS OF SENDER (Please do not use customer number below):

McDermott Will & Emery
28 State Street
Boston, MA 02109

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<210> 1
 <211> 1689
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> modified_base
 <222> (1291)..(1291)
 <223> a, c, t, g, unknown or other
 <400> 1

```

aatcccttttc ctggcacctc tgatatcctt ttgaaattca tgttaaagaa tccctaggct      60
gctatcacat gtggcatctt tgttgagtac atgaataaat caactgggtg gttttacgaa      120
ggatgattat gcttcattgt gggattgtat ttttcttctt ctatcacagg gagaagtgaa      180
atgacaacct cactagatac agttgagacc tttggtacca catcctacta tgatgacgtg      240
ggcctgctct gtgaaaaagc tgataccaga gcactgatgg cccagtttgt gcccccgctg      300
tactccctgg tgttcaactgt gggcctcttg ggcaatgtgg tggtggtgat gatcctcata      360
aaatacagga ggctccgaat tatgaccaac atctacctgc tcaacctggc taactgggac      420
ctgctcttcc tcgtcacctt tccattctgg atccactatg tcaggggggca taactggggt      480
tttggccatg gcatgtgtaa gctcctctca gggttttatc acacaggctt gtacagcgag      540
atctttttca taatcctgct gacaatcgac aggtacctgg ccattgtcca tgctgtgttt      600
gcccttcgag cccggactgt cacttttggg gtcacacca gcacgtcac ctggggcctg      660
gcagtgttag cagctcttcc tgaattttat ttctatgaga ctgaagagtt gtttgaagag      720
actctttgca gtgctcttta cccagaggat acagtatata gctggaggca tttccacact      780
ctgagaatga ccatcttctg tctcgttctc cctctgctcg ttatggccat ctgctacaca      840
ggaatcatca aaacgtgtgt gaggtgcccc agtaaaaaaa agtacaaggc catccggctc      900
atttttgtca tcatggcggg gtttttcatt ttctggacac cctacaatgt ggctatcctt      960
ctctcttctt atcaatccat cttattttgga aatgactgtg agcggacgaa gcactctggac     1020
ctggatcatg tggtgacaga ggtgatcgcc tactccact gctgcatgaa cccgggtgatc     1080
tacgcctttg ttggagagag gttccggaag tacctgcgcc acttcttcca caggcacttg     1140
ctcatgcacc tgggcagata catcccattc ctctctagtg agaagctgga aagaaccagc     1200
tctgtctctc catccacagc agagccggaa ctctctattg tgttttaggt agatgcagaa     1260
aattgcctaa agaggaagga ccaaggagat naagcaaaca cattaagcct tccacactca     1320
cctctaaaaa agtccttcaa accttccagt gcaacactga agctcttaag aactgaaat     1380
atacacacag cagtagcagt agatgcatgt accctaaggt cattaccaca ggccagggtc     1440
gggcagcgta ctcatcatca acctaaaaag cagagctttg cttctctctc taaaatgagt     1500
tacctatatt ttaatgcacc tgaatgttag atagttacta tatgccgcta caaaaaggta     1560
aaacttttta tattttatac attaaactta gccagctatt atataaataa aacattttca     1620
cacaatacaa taagttaact attttatttt ctaatgtgcc tagttctttc cctgcttaat     1680
gaaaagctt
  
```

<210> 2
 <211> 355
 <212> PRT
 <213> Homo sapiens
 <400> 2

```

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
1          5          10          15
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
20        25        30
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
35        40        45
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
50        55        60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
65        70        75        80
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
85        90        95
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
100       105       110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
115       120       125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
  
```

130 135 140
 Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
 145 150 155 160
 Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
 165 170 175
 Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
 180 185 190
 Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
 195 200 205
 Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
 210 215 220
 Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu
 225 230 235 240
 Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
 245 250 255
 Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp
 260 265 270
 Cys Glu Arg Thr Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val
 275 280 285
 Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
 290 295 300
 Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu
 305 310 315 320
 Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
 325 330 335
 Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
 340 345 350
 Ile Val Phe
 355

<210> 3

<211> 1193

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (92)..(1156)

<400> 3

ttgtgcttat ccgggcaaga acttatcgaa atacaataga agaccacgc gtccggtttt 60
 tacttagaag agattttcag ggagaagtga a atg aca acc tca cta gat aca 112
 Met Thr Thr Ser Leu Asp Thr
 1 5
 gtt gag acc ttt ggt acc aca tcc tac tat gat gac gtg ggc ctg ctc 160
 Val Glu Thr Phe Gly Thr Thr Ser Tyr Tyr Asp Asp Val Gly Leu Leu
 10 15 20
 tgt gaa aaa gct gat acc aga gca ctg atg gcc cag ttt gtg ccc ccg 208
 Cys Glu Lys Ala Asp Thr Arg Ala Leu Met Ala Gln Phe Val Pro Pro
 25 30 35
 ctg tac tcc ctg gtg ttc act gtg ggc ctc ttg ggc aat gtg gtg gtg 256
 Leu Tyr Ser Leu Val Phe Thr Val Gly Leu Leu Gly Asn Val Val Val
 40 45 50 55
 gtg atg atc ctc ata aaa tac agg agg ctc cga att atg acc aac atc 304
 Val Met Ile Leu Ile Lys Tyr Arg Arg Leu Arg Ile Met Thr Asn Ile
 60 65 70
 tac ctg ctc aac ctg gcc att tgc gac ctg ctc ttc ctc gtc acc ctt 352
 Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu
 75 80 85
 cca ttc tgg atc cac tat gtc agg ggg cat aac tgg gtt ttt ggc cat 400
 Pro Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His
 90 95 100
 ggc atg tgt aag ctc ctc tca ggg ttt tat cac aca ggc ttg tac agc 448

Gly Met Cys Lys Leu Leu Ser Gly Phe Tyr His Thr Gly Leu Tyr Ser	
105 110 115	
gag atc ttt ttc ata atc ctg ctg aca atc gac agg tac ctg gcc att	496
Glu Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile	
120 125 130 135	
gtc cat gct gtg ttt gcc ctt cga gcc cgg act gtc act ttt ggt gtc	544
Val His Ala Val Phe Ala Leu Arg Ala Arg Thr Val Thr Phe Gly Val	
140 145 150	
atc acc agc atc gtc acc tgg ggc ctg gca gtg cta gca gct ctt cct	592
Ile Thr Ser Ile Val Thr Trp Gly Leu Ala Val Leu Ala Ala Leu Pro	
155 160 165	
gaa ttt atc ttc tat gag act gaa gag ttg ttt gaa gag act ctt tgc	640
Glu Phe Ile Phe Tyr Glu Thr Glu Glu Leu Phe Glu Glu Thr Leu Cys	
170 175 180	
agt gct ctt tac cca gag gat aca gta tat agc tgg agg cat ttc cac	688
Ser Ala Leu Tyr Pro Glu Asp Thr Val Tyr Ser Trp Arg His Phe His	
185 190 195	
act ctg aga atg acc atc ttc tgt ctc gtt ctc cct ctg ctc gtt atg	736
Thr Leu Arg Met Thr Ile Phe Cys Leu Val Leu Pro Leu Leu Val Met	
200 205 210 215	
gcc atc tgc tac aca gga atc atc aaa acg ctg ctg agg tgc ccc agt	784
Ala Ile Cys Tyr Thr Gly Ile Ile Lys Thr Leu Leu Arg Cys Pro Ser	
220 225 230	
aaa aaa aag tac aag gcc atc cgg ctc att ttt gtc atc atg gcg gtg	832
Lys Lys Lys Tyr Lys Ala Ile Arg Leu Ile Phe Val Ile Met Ala Val	
235 240 245	
ttt ttc att ttc tgg aca ccc tac aat gtg gct atc ctt ctc tct tcc	880
Phe Phe Ile Phe Trp Thr Pro Tyr Asn Val Ala Ile Leu Leu Ser Ser	
250 255 260	
tat caa tcc atc tta ttt gga aat gac tgt gag cgg agc aag cat ctg	928
Tyr Gln Ser Ile Leu Phe Gly Asn Asp Cys Glu Arg Ser Lys His Leu	
265 270 275	
gac ctg gtc atg ctg gtg aca gag gtg atc gcc tac tcc cac tgc tgc	976
Asp Leu Val Met Leu Val Thr Glu Val Ile Ala Tyr Ser His Cys Cys	
280 285 290 295	
atg aac ccg gtg atc tac gcc ttt gtt gga gag agg ttc cgg aag tac	1024
Met Asn Pro Val Ile Tyr Ala Phe Val Gly Glu Arg Phe Arg Lys Tyr	
300 305 310	
ctg cgc cac ttc ttc cac agg cac ttg ctc atg cac ctg ggc aga tac	1072
Leu Arg His Phe Phe His Arg His Leu Leu Met His Leu Gly Arg Tyr	
315 320 325	
atc cca ttc ctt cct agt gag aag ctg gaa aga acc agc tct gtc tct	1120
Ile Pro Phe Leu Pro Ser Glu Lys Leu Glu Arg Thr Ser Ser Val Ser	
330 335 340	
cca tcc aca gca gag ccg gaa ctc tct att gtg ttt taggtagatg	1166
Pro Ser Thr Ala Glu Pro Glu Leu Ser Ile Val Phe	
345 350 355	
cagaaaattg cctaaagagg aaggacc	1193

<210> 4

<211> 355

<212> PRT

<213> Homo sapiens

<400> 4

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr	
1 5 10 15	
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu	
20 25 30	
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly	
35 40 45	
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg	

50	55	60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp		
65	70	75
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly		80
	85	90
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe		95
	100	105
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr		110
	115	120
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala		125
	130	135
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu		140
	145	150
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu		155
	165	170
Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val		175
	180	185
Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu		190
	195	200
Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys		205
	210	215
Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu		220
	225	230
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn		235
	245	250
Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp		255
	260	265
Cys Glu Arg Ser Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val		270
	275	280
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val		285
	290	295
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu		300
	305	310
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu		315
	325	330
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser		335
	340	345
Ile Val Phe		350
	355	

<210> 5

<211> 1116

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
consensus sequence

<400> 5

cagggagaag tgaatgaca acctcactag atacagttga gacctttggt accacatcct	60
actatgatga cgtgggcctg ctctgtgaaa aagctgatac cagagcactg atggcccagt	120
ttgtgcccc gctgtactcc ctggtgttca ctgtgggcct cttgggcaat gtggtggtgg	180
tgatgatcct cataaaatac aggaggctcc gaattatgac caacatctac ctgctcaacc	240
tggccatttc ggacctgctc ttctcgtca cccctccatt ctggatccac tatgtcaggg	300
ggcataactg ggtttttggc catggcatgt gtaagctcct ctcagggttt tatcacacag	360
gcttgtagag cgagatcttt ttcataatcc tgctgacaat cgacagggtac ctggccattg	420
tccatgctgt gtttgccctt cgagcccggg ctgtcacttt tgggtgtcatc accagcatcg	480
tcacctgggg cctggcagtg ctagcagctc ttctgaatt tatcttctat gagactgaag	540
agttgtttga agagactmmt tgcagtgtc tttaccaga ggatacagta tatagctgga	600
gssatttcca cactctgaga atgacctct tctgtctcgt tctccctctg ctggttatgg	660
ccatctgcta cacaggaatc atcaaaacgc tgctgaggtg cccagtaaa aaaaagtaca	720
aggccatccg gtcatttttt gtcacatggt cgggtgttttt cattttctgg acaccctaca	780

```

atgtggctat ccttctctct tscywwymaw ycatcttatt tggaaatgac tgtgagcggm      840
mgarsmwyk  ggacctggtc atgctgggtga cagaggtgat cgcctactcc cactgctgca      900
tgaacccggt gatctacgcc tttgttggag agaggttccg gaagtacctg cgccacttst      960
tccacaggca cttgctcatg cacctgggca gatacatccc attccttctt agtgagaagc     1020
tggaaagaac cagctctgtc tctccatcca cagcagagcc ggaactctct attgtgtttt     1080
aggtagatgc agaaaattgc ctaaagagga aggacc                                  1116

```

<210> 6

<211> 355

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
consensus sequence

<220>

<221> MOD_RES

<222> (182)..(182)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (196)..(197)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (263)..(266)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (276)..(279)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (315)..(315)

<223> Any amino acid

<400> 6

```

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
1          5          10          15
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
          20          25          30
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
          35          40          45
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
          50          55          60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
65          70          75          80
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
          85          90          95
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
          100          105          110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
          115          120          125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
          130          135          140
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
145          150          155          160
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
          165          170          175
Leu Phe Glu Glu Thr Xaa Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
          180          185          190
Tyr Ser Trp Xaa Xaa Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
          195          200          205

```

```

Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
 210                      215                      220
Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu
225                      230                      235                      240
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
                      245                      250                      255
Val Ala Ile Leu Leu Ser Xaa Xaa Xaa Xaa Ile Leu Phe Gly Asn Asp
                      260                      265                      270
Cys Glu Arg Xaa Xaa Xaa Xaa Asp Leu Val Met Leu Val Thr Glu Val
                      275                      280                      285
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
                      290                      295                      300
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Xaa Phe His Arg His Leu
305                      310                      315                      320
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
                      325                      330                      335
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
                      340                      345                      350
Ile Val Phe
                      355

```

```

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
       primer
<220>
<221> modified_base
<222> (19)..(19)
<223> Inosine
<220>
<221> modified_base
<222> (24)..(24)
<223> Inosine
<400> 7
tacctgctsa acctggccnt ggcng

```

25

```

<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
       primer
<220>
<221> modified_base
<222> (9)..(9)
<223> Inosine
<220>
<221> modified_base
<222> (14)..(14)
<223> Inosine
<400> 8
acctggccnt ggcngacctm ctctt

```

25

```

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence

```

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (18)..(18)
 <223> Inosine
 <400> 9
 gaccgytacc tggccatngt ccaygcc

27

<210> 10
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (10)..(10)
 <223> Inosine
 <400> 10
 ggcrctggacn atggccaggt arcggtc

27

<210> 11
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (1)..(1)
 <223> Inosine

<220>
 <221> modified_base
 <222> (6)..(6)
 <223> Inosine

<220>
 <221> modified_base
 <222> (16)..(16)
 <223> Inosine

<220>
 <221> modified_base
 <222> (18)..(18)
 <223> Inosine

<400> 11
 naccanrttg tagggnrncc armarag

27

<210> 12
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (8)..(8)
 <223> Inosine

<220>
 <221> modified_base
 <222> (10)..(10)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (23)..(23)
 <223> Inosine
 <400> 12
 tgtagggnrn ccarmaragr agnargaa

28

<210> 13
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (12)..(12)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (15)..(16)
 <223> Inosine
 <400> 13
 gaaggcgtag ansannggt tgasgca

27

<210> 14
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (4)..(4)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (7)..(8)
 <223> Inosine
 <400> 14
 agansanngg gttgasgcag cwgtg

25

<210> 15
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide
 <220>
 <221> CDS
 <222> (16)..(48)
 <400> 15
 aagcttccag cagcc atg gac tac aag gac gac gat gac aaa gaa ttc
 Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe
 1 5 10

48

<210> 16
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 peptide
 <400> 16
 Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe
 1 5 10

<210> 17
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <400> 17
 ttaagaattc acaacctcac tagatac

27

<210> 18
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <400> 18
 catagtggat ccagaatg

18

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.